ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: PUB501

Conjunctival Squamous-Cell Carcinoma after Kidney Transplant

Session Information

Category: Transplantation

  • 2102 Transplantation: Clinical

Author

  • Alnimri, Muna, University of California Davis, Sacramento, California, United States
Introduction

Conjunctival squamous cell cancer (SCC ) is rare affecting HIV patients and elderly exposed to extra UV light, the incidence increases post kidney transplant due to immunosuppression, treatemnt with wide excision,cryotherapy, local chemotherapy and radiation had been successful Prognosis depends on local invasion of the tumor to the orbit and the presence of distal metastasis.Our patient developed SCC 13 years post transplant

Case Description

64 year old Hispanic male farm worker diagnosed with Hypertensive Nephrosclerosis on Hemodialysis received a kidney transplant in 2011 baseline creatinine 1mg/dl was maintained on Tacrolimus 2 mg bid imuran 50 mg as he did not tolerate Mycophenolate Mofetil and prednisone 5 mg .
Presented in 2/24 with a right eye mass, tearing and eye discharge, followed by headach (figure 1) Orbital and head MRI showed fungating mass involving the temporal conjunctiva without invasion to the cornea . Biopsy of the lesion showed SCC. He underwent excision/debulking of the mass and pathology confirmed SCC with positive margins, Oncology consult suggested cryotherapy,local chemotherapy or radiation therapy The patient agreed to local chemptherapy with eye drops . Immunosuppression had been reduced with discontinuing imuran and lowering tacrolimus to a level of 3-5 with 5 mg prednisone.

Discussion

The risk of SCC increases with the duration of immunosuppression, 7% of transplant patients develop SCC after 10 years and 35% after 25 years ,conjuctival SCC is rare with incidence of 0.02-2.8/100000, It usually grows slowly on the epithelial surface of the eye and rarely invades the orbit and spreads distally, treatment is wide excision of the conjunctive with reconstructive flaps, cryotherapy, topical chemotherapeutic eye drops like mytomycin ,5FU and interferon, prognosis is not bad if dicovered early,5 years survival 85%.